Industry
Eirion Therapeutics Inc.
Total Trials
7
Recruiting
0
Active
1
Completed
6
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 7 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
4 of 6 completed trials have results
Key Signals
4 with results
Enrollment Performance
Analytics
Phase 2
6(85.7%)
Phase 1
1(14.3%)
7Total
Phase 2(6)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (7)
Showing 7 of 7 trials
NCT07321834Phase 2Active Not Recruiting
A Study to Evaluate AI-09 In Participants With Glabellar Lines
Role: lead
NCT05565950Phase 1Completed
AI-09 In Subjects With Glabellar Lines, GL-101
Role: lead
NCT04985916Phase 2Completed
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Role: lead
NCT03839693Phase 2Completed
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
Role: lead
NCT03912805Phase 2Completed
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Role: lead
NCT03655691Phase 2Completed
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
Role: lead
NCT03326856Phase 2Completed
ET-01 in Subjects With Lateral Canthal Lines
Role: lead
All 7 trials loaded